CI-1033(Canertinib)/PD-183805

Solubility:10 mmol/L in DMSO

Storage:-20C 2 years

Biologieal

Cediranib (AZD2171) is a once-daily oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. Phase 1 studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less.

Reference

1. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Marcus Bantscheff, Dirk Eberhard, etal. Nature Biotechnology; 1087-0156; 2007; 25(9) ; 1035-1044 2. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. Nikolinakos P, Heymach JV. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S131-4 3. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, J��rgensmeier JM, Alitalo K. Cancer Res. 2008 Jun 15;68(12):4754-62